Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-541468 dose-response PSG study in adults with insomnia disorder
2016-000826-21Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of daridorexant in Insomnia (3 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Change in wake after sleep onset. Started Aug 2016; status: completed.
02
Drugs
daridorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on 2016-000826-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000826-21.